TimeTeller GmbH, founded in 2023, is a promising player in the healthcare innovation landscape, operating out of Germany. With the compelling slogan, "Time matters and it's time to use it!", the company is strategically positioned to disrupt the industry by leveraging the science of circadian rhythms. Their technology profiles circadian clocks via molecular analysis of saliva and computational modelling to enhance the timing of treatment regimes, particularly in cancer therapy.
Originating as a spin-off from Charité Universitätsmedizin Berlin, TimeTeller is rooted in robust academic research led by Angela Relógio, in collaboration with healthcare and pharmaceutical sectors. Initial backing came from the "Inventors for Health" program by the Stiftung Charité and the Digital Health Accelerator program by the Berlin Institute of Health. Current funding is through the InnorampUp program of the IFB.
Though exactly how much financial backing it has amassed remains undisclosed, TimeTeller shows significant potential for scalable impact and return on investment by integrating circadian rhythm insights into mainstream drug development and healthcare practice.